OSE Immunotherapeutics Publishes Preclinical Efficacy Results for Lusvertikimab in ALL

OSE Immunotherapeutics announced that its preclinical efficacy data for Lusvertikimab in treating B- and T-Cell Acute Lymphoblastic Leukemia (ALL) has been published in the journal ‘Blood’. This research, conducted in collaboration with the University Medical Center Schleswig-Holstein, Kiel, shows promising results using patient-derived samples and in-vivo xenograft models.

The study highlights Lusvertikimab's dual action: blocking IL-7 receptor signaling and inducing antibody-dependent cellular phagocytosis. This approach aims to address the high IL-7R expression in 85% of ALL patients, offering a potential new immunotherapy, especially when combined with standard chemotherapies.

Nicolas Poirier, CEO of OSE Immunotherapeutics, emphasized the need for novel therapies to improve outcomes for patients with B-ALL and T-ALL, and appreciated the collaborative effort with leading hematology researchers in Kiel.